Product Data Sheet

Product Name:	Cytochrome P450 CYP1B1 (190-198) [Homo sapiens]
Cat. No.:	GP10141

Chemical Properties

Cas. No.			
SMILES	NC(C(NC(CC(C)C)C(NC(CC(O)=O)C(N1C(C(NC(CCCNC(N)=N)C(N2CCCC2C(NC(CC(C)C)C(NC(C(C)O)C(NC(C(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=		
Formula	$C_{50}H_{80}N_{12}O_{13}$	M.Wt	1057.24
Solubility	≥ 105.7mg/mL in DMSO	Storage	Store at -2(
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure	Cytochrome P450 CYP1B1 (190-198) [Homo sapiens]		

Background

H2N-FLDPRPLTV-OH
Cytochrome P450 CYP1B1 is a dioxin-inducible form of the cytochrome P450 family of xenobiotic metabolizing enzymes1.
HLA-A2 restricted, CYP1B1 190–198 (CYP190) peptide specific T cell responses are induced in HLA-A2Kb transgenic mice by immunization with ZYC300, a PLG microparticle formulation that contains a plasmid DNA encoding the tumor associated antigen CYP1B12, 3.
Each successive co-application of EPT contributes to an escalating T cell response that can be observed 2 weeks after the last immunization, and that even a single EPT when given with the usually ineffective 30 µg dose of ZYC300 was able to induce a detectable CD8+ CYP190 specific T cell response4.

References:
1. Murray,G.I., Taylor, M. C., et al 1997; Tumor-specific Expression of Cytochrome P450 CYP1B11. Cancer Research. 57:3026-3031.
2. Luby TM, Cole GA, Baker L, Kornher JS, Ramstedt U, Hedley ML. Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor associated antigen cytochrome P450 1B1. Clinical Immunology 2004;112(1):45–53.
3. Maecker DH, Sherr RH, Vonderheide MS, von Bergwelt-Baildon MS, Hirano N, Anderson K, et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood 2003;102(9):3287–94.
4. Barbon, C. M., Baker, L et al 2010 In vivo electroporation enhances the potency of poly-lactide co-glycolide (PLG) plasmid DNA immunization. Vaccine; 28:7852-7864

Caution: Product has not been fully validated for medical applications. For research use only.
Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA